Patients are routinely monitored for rising PSA levels as more than a third of patients will have their cancer recur within 10 years.17 When PSA levels rise, the treatment options may impact quality of life, introducing potential for non-toxic low-dose radiation therapy to eliminate those negative options. The gene discussed is KLK3; the disease is cancer.